Torcetrapib: Atherosclerosis therapy cholesteryl ester transfer protein (CETP) inhibitor

Drugs of the Future

Volumn 30, Issue 4, 2005, Pages 344-349

  McIntyre, J A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB;

ADULT; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; MULTIPLE DRUG DOSE; NONHUMAN; PERIPHERAL VASCULAR DISEASE; RABBIT; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 21744441963     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.04.898153     Document Type: Review

References (20)

1. DeNinno, M.P., Magnus-Aryitey, G.T., Ruggeri, R.B., Wester, R.T. (Pfizer Products Inc.). 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as CETP inhibitors. EP 1114031, JP 2002526475, JP 2004339239, US 6197786, WO 0017164.
2. Allen, D.J.M., Appleton, T.A., Brostrom, L.R., Tickner, D.L. (Pfizer Products Inc.). 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor. EP 1246804, JP 2003515592, WO 0140190.
3. Damon, D.B., Dugger, R.W. (Pfizer Products Inc.). Method for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonylamino] -2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester. CA 2327029, EP 1125929, US 6313142.
4. Damon, D.B., Dugger, R.W., Scott, R.W. (Pfizer Products Inc.). Cpds. useful as intermediates. WO 0288069.
5. Damon, D.B., Dugger, R.W., Scott, R.W. (Pfizer Products Inc.). Methods for preparing CETP inhibitors. WO 0288085.
6. Prous Science Drug R&D Backgrounders: Atherosclerosis (online publication). Updated May 2, 2005.
7. Tegos, T.J., Kalodiki, E., Sabetai, M.M., Nicolaides, A.N. The genesis of atherosclerosis and risk factors: A review. Angiology 2001, 52: 89-98.
8. Barter, P.J., Brewer, H.B. Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23: 160-7.
9. Ruggeri, R.B., Wester, R.T., Magnus-Aryitey, G. Discovery of CP-529,414: A potent synthetic inhibitor of human plasma cholesteryl ester transfer protein (CETP). 225th ACS Natl Meet (March 23-27, New Orleans) 2003, Abst MEDI 156.
10. Morehouse, L.A., Sugarman, E.D., Bourassa, P.-A., Milici, A.J. HDL elevation by the CETP-inhibitor torcetrapib prevents aortic atherosclerosis in rabbits. Circulation 2004, 110(17, Suppl. 3): Abst 1168.
11. Morehouse, L.A., Sugarman, E.D., Bourassa, P.A., Milici, A.J. The CETP-inhibitor torcetrapib raises HDL and prevents aortic atherosclerosis in rabbits. 5th Int Symp Drugs Affect Lipid Metab (Oct 24-27, Venice) 2004, 41.
12. Clark, R.W., Sutfin, T.A., Ruggeri, R.B. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24: 490-7.
13. Brousseau, M.E., Schaefer, E.J., Wolfe, M.L., Bloedon, L.T., Digenio, A.G., Clark, R.W., Mancuso, J.P., Rader, D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New Engl J Med 2004, 350: 1505-15.
14. Brousseau, M.E., Diffenderfer, M.R., Millar, J.S. et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies and apolipoprotein A-I metabolism. Circulation 2004, 110(17, Suppl. 3): Abst 684.
15. Davidson, M., McKenney, J., Revkin, J., Shear, C. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor torcetrapib when administered with and without atorvastatin to subjects with a low level of high-density lipoprotein cholesterol. 54th Annu Sci Sess Am Coll Cardiol (March 6-9, Orlando) 2005, Abst 802-3.
16. Lloyd, D.B., Lira, M.E., Wood, L.S. et al. Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. J Biol Chem 2005, 280(15): 14918-22.
17. Pfizer reviews recent developments. DailyDrugNews.com (Daily Essentials) April 12, 2005.
18. Kastelein, J.J.P., Bots, M.L., Riley, W.A., Evans, G.W., Meijer, R., Revkin, J.H., Raszewska, J., Shear, C.L., Thuren, T. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis in patients with familial hypercholesterolemia. 75th Eur Atheroscler Soc Congr (April 23-26, Prague) 2005, Abst W10-P-018.
19. Nissen, S.E., Tardif, J.-C., Crowe, T., Thuren, T., Shear, C.L., Revkin, J.H. Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease. 75th Eur Atheroscler Soc Congr (April 23-26, Prague) 2005, Abst W16-P-060.
20. Bots, M.L., Riley, W.A., Evans, G.W., Kastelein, J.J.P., Revkin, J.H., Thuren, T., Shear, C.L., Nguyen, T.T. Design of a study of the effect of torcetrapib/atorvastatin versus atorvastatin alone on intima-media thickness in patients with mixed hyperlipidemia. 75th Eur Atheroscler Soc Congr (April 23-26, Prague) 2005, Abst W10-P-004.